A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

552 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study compares the safety and immunogenicity profile of several travel vaccines given alone or concomitantly with MenACWY-CRM to healthy adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

NCT01453348

Meningococcal Disease Meningococcal Meningitis Hepatitis A +1 more

COMPLETED PHASE3

Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects

NCT01662440

Rabies Japanese Encephalitis

COMPLETED PHASE3

Novartis Vaccine and Diagnostics Carriage Trial

NCT01214850

N. Meningitidis Carriage

COMPLETED PHASE3

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon

NCT03869866

Healthy Volunteers (Meningococcal Infection)

COMPLETED PHASE3

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents

NCT00518180

Meningococcal Meningitis Human Papillomavirus Infection Pertussis +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meningococcal Disease Meningococcal Meningitis Typhoid Yellow Fever Rabies Japanese Encephalitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TF+YF

Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.

Group Type ACTIVE_COMPARATOR

Typhoid Vi Polysaccharide Vaccine

Intervention Type BIOLOGICAL

One dose of typhoid Vi polysaccharide vaccine.

Yellow Fever Vaccine

Intervention Type BIOLOGICAL

One dose of yellow fever vaccine.

TF + YF + MenACWY-CRM197

Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.

Group Type ACTIVE_COMPARATOR

Typhoid Vi Polysaccharide Vaccine

Intervention Type BIOLOGICAL

One dose of typhoid Vi polysaccharide vaccine.

Yellow Fever Vaccine

Intervention Type BIOLOGICAL

One dose of yellow fever vaccine.

MenACWY-CRM Vaccine

Intervention Type BIOLOGICAL

One dose of MenACWY-CRM vaccine.

JE + Rabies

Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.

Group Type ACTIVE_COMPARATOR

Japanese Encephalitis Vaccine

Intervention Type BIOLOGICAL

Two doses of Japanese Encephalitis Vaccine.

Rabies Vaccine

Intervention Type BIOLOGICAL

Three doses of Rabies vaccine.

JE + Rab + MenACWY-CRM197

Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.

Group Type ACTIVE_COMPARATOR

Japanese Encephalitis Vaccine

Intervention Type BIOLOGICAL

Two doses of Japanese Encephalitis Vaccine.

Rabies Vaccine

Intervention Type BIOLOGICAL

Three doses of Rabies vaccine.

MenACWY-CRM Vaccine

Intervention Type BIOLOGICAL

One dose of MenACWY-CRM vaccine.

Rabies

Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.

Group Type ACTIVE_COMPARATOR

Rabies Vaccine

Intervention Type BIOLOGICAL

Three doses of Rabies vaccine.

MenACWY-CRM197 (Combined)

Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.

Group Type ACTIVE_COMPARATOR

MenACWY-CRM Vaccine

Intervention Type BIOLOGICAL

One dose of MenACWY-CRM vaccine.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Typhoid Vi Polysaccharide Vaccine

One dose of typhoid Vi polysaccharide vaccine.

Intervention Type BIOLOGICAL

Yellow Fever Vaccine

One dose of yellow fever vaccine.

Intervention Type BIOLOGICAL

Japanese Encephalitis Vaccine

Two doses of Japanese Encephalitis Vaccine.

Intervention Type BIOLOGICAL

Rabies Vaccine

Three doses of Rabies vaccine.

Intervention Type BIOLOGICAL

MenACWY-CRM Vaccine

One dose of MenACWY-CRM vaccine.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Female and male subjects who must be healthy and must be:

1. Between 18 and 60 years of age inclusive and who have given their written informed consent;
2. Available for all visits and telephone calls scheduled for the study;
3. In good health as determined by medical history, physical examination and clinical judgment of the investigator;
4. For female subjects, having a negative urine pregnancy test.

Exclusion Criteria

Individuals not eligible to be enrolled in the study are those:

1. who are breastfeeding;
2. who have a personal history of Neisseria meningitidis infection, typhoid fever, rabies, or any flavivirus infection (e.g., Japanese encephalitis, tick-borne encephalitis, yellow fever, dengue fever, West Nile virus infection);
3. who have been immunized with any of the study vaccines within the last five years as determined by medical history and/or vaccination card;
4. who have received investigational agents or vaccines within 30 days prior to enrollment or who expect to receive an investigational agent or vaccine prior to completion of the study;
5. who have received live licensed vaccines within 30 days and inactive vaccine within 15 days prior to enrollment or for whom receipt of a licensed vaccine is anticipated during the study period.

(Exception: Influenza vaccine may be administered up to 15 days prior to each study immunization and no less than 15 days after each study immunization);
6. who have received an anti-malaria drug, up to 2 months prior to the study;
7. who have experienced, within the 7 days prior to enrollment, significant acute infection (for example requiring systemic antibiotic treatment or antiviral therapy) or have experienced fever (defined as body temperature ≥ 38°C) within 3 days prior to enrollment;
8. who have any serious acute, chronic or progressive disease such as:

* history of cancer
* complicated diabetes mellitus
* advanced arteriosclerotic disease
* autoimmune disease
* HIV infection or AIDS
* blood dyscrasias
* congestive heart failure
* renal failure
* severe malnutrition (Note: Subjects with mild asthma are eligible for enrollment. Subjects with moderate or severe asthma requiring routine use of inhaled or systemic corticosteroids are not eligible for enrollment);
9. who have epilepsy, any progressive neurological disease or history of Guillain-Barre syndrome;
10. who have a history of anaphylaxis, serious vaccine reactions, or allergy to any vaccine component, including but not limited to latex allergy, egg allergy, antibiotic allergy, chicken proteins or gelatin allergy;
11. who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):

* receipt of immunosuppressive therapy within 30 days prior to enrollment (systemic corticosteroids administered for more than 5 days, or in a daily dose \> 1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy);
* receipt of immunostimulants;
* receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study;
12. who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time;
13. who have myasthenia gravis; thyroid or thymic disorders,
14. who have any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives;
15. who are part of the study personnel or close family members of those conducting this study.
16. for whom a long-term stay (≥ 1 month) was planned in Africa, Latin America, or Asia.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes